Enforcement
We enforce federal competition and consumer protection laws that prevent anticompetitive, deceptive, and unfair business practices.
,
Search or browse
the Legal Library
Find legal resources and guidance to understand your business responsibilities and comply with the law.
,
Take action
- Report an antitrust violation
- File adjudicative documents
- Find banned debt collectors
- View competition guidance
,
Competition Matters,
,
Policy
We work to advance government policies that protect consumers and promote competition.
,
Search or browse
the Legal Library
Find legal resources and guidance to understand your business responsibilities and comply with the law.
,
Take action
,
Technology Blog,
Simon Fondrie-Teitler, Office of Technology,
,
Advice and Guidance
Learn more about your rights as a consumer and how to spot and avoid scams. Find the resources you need to understand how consumer protection law impacts your business.
,
Take action
- Report fraud
- Report identity theft
- Register for Do Not Call
- Sign up for consumer alerts
- Get Business Blog updates
- Get your free credit report
- Find refund cases
- Order bulk publications
,
Consumer Advice
- Shopping and Donating
- Credit, Loans, and Debt
- Jobs and Making Money
- Unwanted Calls, Emails, and Texts
- Identity Theft and Online Security
- Scams
,
Business Guidance
- Advertising and Marketing
- Credit and Finance
- Privacy and Security
- By Industry
- For Small Businesses
- Browse Business Guidance Resources
- Business Blog
,
Servicemembers:
Your tool for financial readiness
,
Get consumer protection basics, plain and simple
,
Learn how the FTC protects free enterprise and consumers
,
Looking for competition guidance?
,
News and Events
,
,
–
,
Follow us on social media
,
About the FTC
Our mission is protecting consumers and competition by preventing anticompetitive, deceptive, and unfair business practices through law enforcement, advocacy, and education without unduly burdening legitimate business activity.
,
Looking for legal documents or records? Search the Legal Library instead.
,
Looking for legal documents or records? Search the Legal Library instead.
,
For Release,
Comment submitted to NIST supports the use of march-in rights as a check on inflated pharmaceutical prices,
,
Today the Federal Trade Commission issued a comment in response to the National Institute of Standards and Technology’s (NIST) request for information on its Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights under the Bayh-Dole Act.
Under the Bayh-Dole Act, the federal government has the right to “march in” on patents on inventions created using taxpayer funds—to require the patent holder to license the federally funded patent to other applicants. The draft interagency framework provides guidance outlining when the government should exercise its march-in rights, which have never before been utilized. The draft framework makes clear that high price is an appropriate basis for exercising march-in rights.
In the comment, the FTC applauds NIST, which is part of the U.S. Department of Commerce, and the Interagency Working Group for Bayh-Dole, which includes the U.S. Department of Health and Human Services, for their efforts to reactivate march-in rights as an important check on companies charging Americans inflated prices for drugs developed with taxpayer-funded research. In the comment, the FTC expressed support for an expansive and flexible approach to march-in rights, including providing that agencies can march in on the basis of high prices.
The FTC’s comment draws on its experience in promoting competition and combatting anticompetitive practices in the pharmaceuticals industry. Lack of competition in pharmaceutical markets can lead to inflated pricing, rendering some lifesaving treatments out of reach for many Americans. Nearly three in 10 Americans report rationing or skipping their medications due to high costs. Contrary to industry claims that high drug prices are necessary to fund research and development (R&D), drug prices often depend more on whether the drug faces competition than the drug’s R&D costs. At the same time, pharmaceutical firms enjoy hundreds of billions of dollars of taxpayer investment in R&D. March-in rights are an essential check to ensure that taxpayer-funded inventions are affordable and accessible to the public.
The FTC’s comment further explains that although march-in rights can be a valuable tool to address potential harms in the pharmaceutical industry, broader challenges requiring government-wide solutions remain. For example, dense “patent thickets” result from pharmaceutical companies using increasingly large patent portfolios to protect a single treatment. This may weaken the utility of march-in rights to provide affordable public access to drugs because some pharmaceuticals may be protected by patent thickets that include privately funded blocking patents in addition to government-funded patents subject to march-in rights. In its comment, the FTC urges agencies to work collaboratively to also address such patent thickets.
The Commission voted 3-0 to approve filing of the comment.
,
The Federal Trade Commission develops policy initiatives on issues that affect competition, consumers, and the U.S. economy. Like the FTC on Facebook, follow us on Twitter, read our blogs, and subscribe to press releases for the latest FTC news and resources.
,
Office of Public Affairs,
415-848-5121
